Screener / SEC EDGAR /CIK 0000790526 /10-K filed Mar 2, 2026, compared with Mar 3, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Labs

RadNet, Inc. RDNT

Compare with peers Embed
New in the 10-K 2 paragraphs with nothing like them in the 10-K filed Mar 3, 2025 New in the 10-Q 40 paragraphs not in the 10-Q filed Aug 10, 2026 10-Q against the 10-K 13 risk factor paragraphs and sentences added or reworded

New risk paragraphs, branching off last year

Each branch is a paragraph in Risk Factors with nothing like it in the 10-K filed Mar 3, 2025. A box jumps to the paragraph as filed, below.

2 new

Paragraphs with nothing like them in last year's 10-K

Quoted exactly

2 paragraphs in Risk Factors of the 10-K filed Mar 2, 2026 with nothing like them in the 10-K filed Mar 3, 2025. Quoted exactly. Paragraphs that were only edited are under 10-K change.

management agreements may be curtailed or eliminated due to the radiology groups’ own financial difficulties, loss of physicians or other circumstances.

Read in the 10-K

contamination or injury from these hazardous materials. Although we maintain professional liability insurance coverage in amounts we believe is consistent with industry practice in the event of an accident, we could be held liable for any resulting damages, and any liability could exceed the limits of or fall outside the coverage of our professional liability insurance.

Read in the 10-K

Paragraphs in the 10-Q filed Nov 9, 2026 that were not in the one before

New in the latest 10-Q

40 paragraphs in the 10-Q filed Nov 9, 2026 with nothing like them in the 10-Q filed Aug 10, 2026 (at least half the words must differ; new numbers alone do not count). Quoted exactly, grouped by the item heading above them. This is text that changed, not a judgement of how serious it is.

Financial statements and notes

On August 1, 2026, in connection with the formation of Maryland Imaging Partners, LLC (“MIP”) with the University of Maryland Medical System Corporation (“UMMS”), we obtained control of Advanced Imaging at St. Joseph Medical Center, LLC (“St. Joseph”) and Baltimore Washington Imaging, LLC (“BWI”) through the contribution of the parties’ respective ownership interests in existing joint ventures to MIP. As a result, we obtained an indirect 80 % economic interest in these entities through MIP and recognized net noncash assets acquired with a fair value of $ 26.5 million, without additional cash consideration for these acquisitions. We also recognized a noncash remeasurement gain of $ 7.5 million related to our previously held equity method investments. See Note 4, Business Combinations and Related Activity.

Read in the 10-Q

On August 17, 2026, we issued 34,069 shares of common stock to settle the contingent consideration liabilities as part of our purchase of See-Mode Technologies Pte. Ltd on June 2, 2025. The shares were ascribed a value of $ 2.6 million.

Read in the 10-Q

liabilities, the accuracy of fixed asset valuations, and other customary purchase accounting adjustments. The fair value determination is preliminary and may be updated as additional information becomes available.

Read in the 10-Q

Maryland Imaging Partners, LLC On August 1, 2026, we completed the formation of MIP, a partnership with the UMMS. The operation offers multi-modality services out of 19 locations throughout the state of Maryland. In connection with the transaction, certain RadNet subsidiaries contributed five imaging center locations to Advanced/Upper Chesapeake Health Center, LLC (“Upper Chesapeake”). Subsequently, we and UMMS contributed our respective ownership interests in six existing joint ventures, including Upper Chesapeake and the St. Joseph and BWI imaging businesses, in which we previously held 49 % and 35 % equity method investments, respectively, to MIP.

Read in the 10-Q

As a result of the transaction, we have an 80 % controlling economic interest in MIP, and UMMS holds a 20 % noncontrolling economic interest in MIP. We recognized an increase of $ 8.8 million to additional paid-in capital related to changes in ownership interests in the previously consolidated operations. As a result of the transaction, we obtained control of St. Joseph and BWI and began consolidating their results on August 1, 2026. The step-up in valuation from our existing equity method investments caused the Company to recognize a gain of $ 7.5 million, which is included in Other Income within the Consolidated Statements of Operations. The fair values of the acquired assets and assumed liabilities, including goodwill, are presented in the table above.

Read in the 10-Q
Show the other 35

In connection with the acquisitions, the acquisition-date fair value of the noncontrolling interests was estimated by applying the respective ownership percentages to the estimated fair values of the acquired businesses. The underlying fair values were determined using an income approach, with significant inputs including projected future cash flows and discount rates.

Read in the 10-Q

The following is a listing of annual principal maturities of notes payable exclusive of all related discounts and repayments on our revolving credit facilities as of September 30, 2026 (in thousands)

Read in the 10-Q

maximum level, and 121,370 shares ( 200 % of target) were earned. These were settled as 121,370 shares of RSUs. The earned awards vested in two equal installments on March 10, 2025 and March 10, 2026, subject to continued service. As of September 30, 2026, all 121,370 shares had vested.

Read in the 10-Q

On October 1, 2026, we acquired substantially all of the assets of VRC Holdings, LLC and Valley Radiology Consultants Medical Group, Inc. (collectively, “Valley Radiology Consultants”) for total purchase consideration of approximately $ 7.0 million. Valley Radiology Consultants operates three imaging centers located in Southern California.

Read in the 10-Q

On October 1, 2026, we acquired substantially all of the assets of URMA LLC and University Diagnostic Medical Imaging, P.C. (collectively, “UDMI”) for total purchase consideration of approximately $ 10.0 million. UDMI operates one imaging center located in the Bronx, New York.

Read in the 10-Q

On October 8, 2026, we acquired 11.4 million shares of Series E preferred stock of Imagen Technologies, Inc. (“Imagen”) for approximately $ 35.0 million. In connection with the investment, we entered into commercial agreements for the provision and distribution of DeepHealth software solutions and a data partnership agreement granting Imagen access to certain imaging data for artificial intelligence development and commercialization. Under the data partnership agreement, we received a warrant to purchase up to 7.2 million shares of Imagen common stock at an exercise price of $ 0.01 per share, which vests based on the volume of imaging studies requested, provided and accepted.

Read in the 10-Q

On October 26, 2026, we entered into a definitive agreement to acquire ONRAD, Inc. ("ONRAD"), a provider of teleradiology and in-hospital radiology staffing services. Under the terms of the agreement, we will pay $ 350.0 million in cash, subject to customary adjustments, and issue 5.0 million shares of our common stock at closing. The agreement also provides for additional contingent consideration of up to $ 210.0 million based on ONRAD's achievement of a specified adjusted EBITDA target for the year ending December 31, 2027, payable in cash, shares of our common stock, or a combination thereof. The transaction is subject to customary regulatory approvals and closing conditions and is expected to close during the first quarter of 2027.

Read in the 10-Q

We continued to make significant progress expanding the deployment of our DeepHealth solutions across RadNet imaging centers to drive clinical productivity, reduce operating costs, and enhance the patient experience. Key developments during the quarter included the continued expansion of Reporting Pro, our proprietary diagnostic reporting solution, to sites in Arizona, California, Indiana and the Northeast, and we expect to complete deployment across our network by the first quarter of 2027. We also deployed automated draft reporting technology for X-ray exams, our highest-volume modality at more than 2.8 million procedures annually, using our existing Gleamer X-ray AI workflow. Within our imaging centers, we began transitioning our patient self-registration tool from pilot to a broader rollout and started a regional rollout of our Breast Ultrasound AI solution.

Read in the 10-Q

Advanced Imaging at St. Joseph Medical Center, LLC: 4 imaging centers in Maryland

Read in the 10-Q

The increase in same center professional fees was primarily attributable to higher procedural volumes, partially offset by the use of lower-cost contractors to provide coverage and modest productivity improvements from the continued deployment of DeepHealth tools across our imaging centers. These factors contributed to professional fees increasing at a lower rate than the 9.6% increase in same center revenue.

Read in the 10-Q

Medical supplies expense on a same center basis decreased $0.2 million, or 0.7%, primarily due to lower pricing resulting from renegotiated supplier contracts. This decrease was partially offset by increased utilization of high-cost isotope tracers associated with growth in PET and CT procedures, particularly for prostate cancer and suspected Alzheimer’s studies.

Read in the 10-Q

For the three months ended September 30, 2026, we recognized a gain of $7.5 million in connection with the formation of Maryland Imaging Partners, LLC (“MIP”) on August 1, 2026. The gain represents the difference between the fair value and carrying value of our previously held equity interests in the Advanced Imaging at St. Joseph Medical Center, LLC (“St. Joseph”) and Baltimore Washington Imaging, LLC (“BWI”) imaging businesses upon obtaining control. No comparable gain was recognized during the three months ended September 30, 2025.

Read in the 10-Q

Medical supplies expense on a same center basis increased $6.0 million, or 6.7%, primarily due to higher utilization of high-cost isotope tracers associated with growth in PET and CT procedures, particularly for prostate cancer and suspected Alzheimer’s studies. This increase was partially offset by lower pricing resulting from renegotiated supplier contracts, contributing to slower growth in medical supplies expense relative to same-center revenue.

Read in the 10-Q

For the nine months ended September 30, 2026, we recognized a gain of $7.5 million in connection with the formation of MIP on August 1, 2026. The gain represents the difference between the fair value and carrying value of our previously held equity interests in the St. Joseph and BWI imaging businesses upon obtaining control. No comparable gain was recognized during the nine months ended September 30, 2025.

Read in the 10-Q

3. Represents revenue from imaging centers that underwent changes in consolidation status during the periods presented. Such revenue is presented separately to maintain comparability of systemwide same-center revenue.

Read in the 10-Q

On October 26, 2026, we entered into that certain Agreement and Plan of Merger (the “Merger Agreement”) with Radnet Management, Inc., our direct wholly owned subsidiary (the “Purchaser”), OnRad, Inc. (“ONRAD”), Red Rover Merger Sub, LLC, a direct wholly owned subsidiary of Purchaser (the “Surviving Merger Sub”), Javelin Merger Sub, Inc., a direct wholly owned subsidiary of the Surviving Merger Sub (the “First Merger Sub,” and together with Surviving Merger Sub, the “Merger Subs”), and, solely for purposes of the specified provisions therein, Housatonic IV CF, L.P., a Delaware limited partnership, solely in its capacity as the securityholder representative.

Read in the 10-Q

Pursuant to the Merger Agreement, and subject to the terms and conditions set forth therein, (a) First Merger Sub will merge with and into ONRAD, with ONRAD surviving the First Merger as a direct wholly owned subsidiary of Surviving Merger Sub (the “First Merger”), and (b) immediately thereafter, OnRad will merge with and into Surviving Merger Sub, with Surviving Merger Sub surviving the Second Merger as a direct wholly owned subsidiary of Purchaser (the “Second Merger,” and, together with the First Merger, the “Mergers”).

Read in the 10-Q

At the closing of the Mergers (the “Closing”), the holders (the “ONRAD Holders”) of ONRAD’s common stock, par value $0.0001 per share (the “ONRAD Common Stock”) (including any then outstanding shares of ONRAD Common Stock into which the holders of ONRAD’s outstanding preferred stock and warrants have converted in accordance with the Merger Agreement, but in all cases excluding Dissenting Shares (as defined in the Merger Agreement)) and the holders of Vested Company Options (as defined in the Merger Agreement) will receive an aggregate of (i) $350,000,000 in cash, subject to customary adjustments for cash, indebtedness, net working capital and transaction expenses and subject to certain escrow holdbacks, and (ii) 5,000,000 shares (the “Closing Shares”) of our common stock.

Read in the 10-Q

In addition, the ONRAD Holders may also be entitled to an earn-out payment of up to $210,000,000 (the “Earn-Out Amount”) if ONRAD achieves a certain target Post-Closing Annual Adjusted EBITDA (as defined in the Merger Agreement) for the fiscal year ending December 31, 2027. The Earn-Out Amount may be paid in cash, shares of our common stock or a combination thereof subject to certain tax-related requirements.

Read in the 10-Q

Risk Factors

Completion of the Mergers is subject to certain conditions and if these conditions are not satisfied, waived or fulfilled in a timely manner, the Mergers may be delayed or not completed.

Read in the 10-Q

The obligation of each of RadNet, Purchaser, ONRAD, and the Merger Subs to complete the Mergers is subject to the satisfaction (or, to the extent permitted by applicable law, waiver) of a number of conditions set forth in the Merger Agreement, including customary regulatory approvals and closing conditions.

Read in the 10-Q

Many of the conditions to completion of the Mergers are not within our or ONRAD’s control, and neither we nor ONRAD can predict when, or if, these conditions will be satisfied. If any of these conditions are not satisfied or waived prior to the termination date set forth in the Merger Agreement, it is possible that the Merger Agreement may be terminated. Although the parties to the Merger Agreement have agreed to cooperate with each other and take all actions necessary, proper or advisable to consummate the transactions contemplated by the Merger Agreement as promptly as reasonably practicable, these and other conditions to the completion of the Mergers may fail to be satisfied. In addition, satisfying the conditions to and completion of the Mergers may take longer, and could cost more, than we expect.

Read in the 10-Q

Furthermore, the requirements for obtaining the required regulatory clearances and approvals could delay the completion of the Mergers for a significant period of time or prevent the Mergers from occurring. Any delay in completing the Mergers may adversely affect the cost savings and other benefits that we expect to achieve if the Mergers and the integration of ONRAD’s business are not completed within the expected time frame.

Read in the 10-Q

There can be no assurance that the conditions to the Closing will be satisfied, waived or fulfilled in a timely fashion or that the Mergers will be completed.

Read in the 10-Q

For additional information related to the Merger Agreement, please refer to our Current Report on Form 8-K filed with the SEC on October 26, 2026 (the “October Form 8-K”). The foregoing description of the Merger Agreement is qualified in its entirety by reference to the full text of the Merger Agreement attached as Exhibit 2.1 to the October Form 8-K and as Exhibit 2.1 filed herewith.

Read in the 10-Q

Our business relationships may be subject to disruption due to uncertainty associated with the Mergers.

Read in the 10-Q

Parties with which we do business may experience uncertainty associated with the Mergers, including with respect to current or future business relationships with us. Our business relationships may be subject to disruption as parties with which we do business may attempt to negotiate changes in existing business relationships or consider entering into business relationships with parties other than us. These disruptions could have an adverse effect on our business, financial condition, results of operations or prospects, including an adverse effect on our ability to realize the anticipated benefits of the Mergers. The risk, and adverse effect, of such disruptions could be exacerbated by a delay in completion of the Mergers or termination of the Merger Agreement.

Read in the 10-Q

Potential litigation against us could result in substantial costs, an injunction preventing the completion of the Mergers and/or a judgment resulting in the payment of damages.

Read in the 10-Q

Securities class action lawsuits and derivative lawsuits are often brought against public companies that have entered into merger agreements. Even if such lawsuits are unsuccessful, defending against them can result in substantial costs.

Read in the 10-Q

Lawsuits may be filed against us and/or our directors and officers in connection with the Mergers. These lawsuits could prevent or delay the completion of the Mergers and result in significant costs to us, including any costs associated with the indemnification of directors and officers. There can be no assurance that any of the defendants will be successful in the outcome of any potential lawsuits.

Read in the 10-Q

We will incur significant transaction and Merger-related costs in connection with the Mergers.

Read in the 10-Q

We expect to incur a number of non-recurring costs associated with the Mergers and combining the operations of the two companies. The significant, non-recurring costs associated with the Mergers include, among others, fees and expenses of financial, legal, accounting and other advisors and representatives. Some of these costs have already been incurred or may be incurred regardless of whether the Mergers are completed, including a portion of the fees and expenses of advisors and representatives. We also will incur transaction fees and costs related to formulating and implementing integration plans with respect to the two companies, including facilities and systems consolidation costs. We continue to assess the magnitude of these costs, and additional unanticipated costs may be incurred in the Mergers and the integration of the two companies’ businesses.

Read in the 10-Q

Share sales and buybacks

On August 17, 2026, we issued 34,069 shares of our common stock to certain See-Mode Sellers (as defined below) or their respective designees as the share component of the payment for the satisfaction of certain milestone conditions set forth in, and pursuant to, that certain Share Purchase Agreement, dated June 2, 2025, by and among the sellers set forth on Schedule 1 thereto (the “See-Mode Sellers”) and DH AI International Holdings, B.V., our wholly-owned subsidiary incorporated in the Netherlands. The shares were ascribed a value of $2.6 million. The shares were issued in reliance upon the exemption from the registration requirements of the Securities Act pursuant to Section 4(a)(2) of the Securities Act, Rule 506 of Regulation D or Regulation S promulgated under the Securities Act.

Read in the 10-Q

Item 6

Number 101 The following financial information from RadNet, Inc.'s Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 formatted in Inline XBRL (Extensible Business Reporting Language) includes: (i) the Condensed Consolidated Balance Sheets, (ii) the Condensed Consolidated Statements of Operations, (iii) the Condensed Consolidated Statements of Comprehensive Income (Loss), (iv) the Condensed Consolidated Statements of Changes in Stockholders Equity, (v) the Condensed Consolidated ... ───────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────── 2.1 Agreement and Plan of Merger, dated as of October 26, 2026, by and among RadNet, Inc., Radnet Management, Inc., Red Rover Merger Sub, LLC, Javelin Merger Sub, Inc., OnRad, Inc. and, solely for the limited purposes set forth therein, Housatonic IV CF, L.P., as Securityholder Representative (incorporated by reference to Exhibit 2.1 to the Form 8-K filed with the SEC on October 26, 2026)# 3.1 Certificate of Incorporation of RadNet, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 filed with Form 8-K on September 4, 2008) 3.2 Certificate of Amendment to Certificate of Incorporation of RadNet, Inc., a Delaware corporation, dated September 2, 2008 (incorporated by reference to Exhibit 3.2 filed with Current Report on Form 8-K on September 4, 2008). 3.3 Amended and Restated Bylaws of RadNet, Inc., a Delaware corporation (incorporated by reference to Exhibit 3.1 filed with Current Report on Form 8-K on February 6, 2020). 10.1 Form of Restrictive Covenant and Support Agreement, dated October 26, 2026, between Radnet Management, Inc., OnRad, Inc. and certain stockholders of OnRad, Inc. named therein (incorporated by reference to Exhibit 10.1 to the Form 8-K filed with the SEC on October 26, 2026)# 31.1 Certification of Howard G. Berger, M.D. pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 31.2 Certification of Mark D. Stolper pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. 32.1 Certification of Howard G. Berger, M.D. pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. * 32.2 Certification of Mark D. Stolper pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002. * 104 Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

Read in the 10-Q

# Certain schedules and exhibits have been omitted pursuant to Item 601(a)(5) and/or Item 601(b)(2) of Regulation S-K. The Company agrees to furnish supplementally a copy of such schedules and exhibits, or any section thereof, to the SEC upon request; provided, however, that the Company may request confidential treatment pursuant to Rule 24b-2 under the Securities Exchange Act of 1934, as amended, for any exhibits or schedules so furnished.

Read in the 10-Q

The 10-Q's risk factors against the 10-K

Item 1A of the 10-Q filed Nov 9, 2026 against Item 1A of the 10-K filed Mar 2, 2026. A 10-Q repeats only the risks that changed, so a 10-K paragraph that is missing from it is not counted as removed. Added is a paragraph with nothing like it in the 10-K, Reworded a sentence that is in both with several words changed, Quiet changes a sentence in both where one to four words changed and one is a hedge or a modal (cut words struck through, new words highlighted). Text on the page, not a score; each links to the filing at sec.gov.

What the 10-Q itself says about its risk factors:For information about the risks and uncertainties related to our business, please see the risk factors described in our Annual Report. The risks described in our Annual Report are not the only risks facing our Company. Except as provided below, additional risks and uncertainties not currently known to us or that we currently deem to be immaterial also may materially adversely affect our business, financial condition and/or operating results.

Read in the 10-Q
Added10-Q Nov 9, 2026 vs 10-K Mar 2, 2026
Completion of the Mergers is subject to certain conditions and if these conditions are not satisfied, waived or fulfilled in a timely manner, the Mergers may be delayed or not completed.

Read it in the 10-Q at sec.gov

Added10-Q Nov 9, 2026 vs 10-K Mar 2, 2026
The obligation of each of RadNet, Purchaser, ONRAD, and the Merger Subs to complete the Mergers is subject to the satisfaction (or, to the extent permitted by applicable law, waiver) of a number of conditions set forth in the Merger Agreement, including customary regulatory approvals and closing conditions.

Read it in the 10-Q at sec.gov

Added10-Q Nov 9, 2026 vs 10-K Mar 2, 2026
Many of the conditions to completion of the Mergers are not within our or ONRAD’s control, and neither we nor ONRAD can predict when, or if, these conditions will be satisfied. If any of these conditions are not satisfied or waived prior to the termination date set forth in the Merger Agreement, it is possible that the Merger Agreement may be terminated. Although the parties to the Merger Agreement have agreed to cooperate with each other and take all actions necessary, proper or advisable to consummate the transactions contemplated by the Merger Agreement as promptly as reasonably practicable, these and other conditions to the completion of the Mergers may fail to be satisfied. In addition, satisfying the conditions to and completion of the Mergers may take longer, and could cost more, than we expect.

Read it in the 10-Q at sec.gov

Added10-Q Nov 9, 2026 vs 10-K Mar 2, 2026
Furthermore, the requirements for obtaining the required regulatory clearances and approvals could delay the completion of the Mergers for a significant period of time or prevent the Mergers from occurring. Any delay in completing the Mergers may adversely affect the cost savings and other benefits that we expect to achieve if the Mergers and the integration of ONRAD’s business are not completed within the expected time frame.

Read it in the 10-Q at sec.gov

Added10-Q Nov 9, 2026 vs 10-K Mar 2, 2026
There can be no assurance that the conditions to the Closing will be satisfied, waived or fulfilled in a timely fashion or that the Mergers will be completed.

Read it in the 10-Q at sec.gov

Show the other 7
Added10-Q Nov 9, 2026 vs 10-K Mar 2, 2026
For additional information related to the Merger Agreement, please refer to our Current Report on Form 8-K filed with the SEC on October 26, 2026 (the “October Form 8-K”). The foregoing description of the Merger Agreement is qualified in its entirety by reference to the full text of the Merger Agreement attached as Exhibit 2.1 to the October Form 8-K and as Exhibit 2.1 filed herewith.

Read it in the 10-Q at sec.gov

Added10-Q Nov 9, 2026 vs 10-K Mar 2, 2026
Parties with which we do business may experience uncertainty associated with the Mergers, including with respect to current or future business relationships with us. Our business relationships may be subject to disruption as parties with which we do business may attempt to negotiate changes in existing business relationships or consider entering into business relationships with parties other than us. These disruptions could have an adverse effect on our business, financial condition, results of operations or prospects, including an adverse effect on our ability to realize the anticipated benefits of the Mergers. The risk, and adverse effect, of such disruptions could be exacerbated by a delay in completion of the Mergers or termination of the Merger Agreement.

Read it in the 10-Q at sec.gov

Added10-Q Nov 9, 2026 vs 10-K Mar 2, 2026
Potential litigation against us could result in substantial costs, an injunction preventing the completion of the Mergers and/or a judgment resulting in the payment of damages.

Read it in the 10-Q at sec.gov

Added10-Q Nov 9, 2026 vs 10-K Mar 2, 2026
Securities class action lawsuits and derivative lawsuits are often brought against public companies that have entered into merger agreements. Even if such lawsuits are unsuccessful, defending against them can result in substantial costs.

Read it in the 10-Q at sec.gov

Added10-Q Nov 9, 2026 vs 10-K Mar 2, 2026
Lawsuits may be filed against us and/or our directors and officers in connection with the Mergers. These lawsuits could prevent or delay the completion of the Mergers and result in significant costs to us, including any costs associated with the indemnification of directors and officers. There can be no assurance that any of the defendants will be successful in the outcome of any potential lawsuits.

Read it in the 10-Q at sec.gov

The first 12 of 13 are shown (at most 12 of each type).

Phrases used for the first time

Two-word phrases in Risk Factors of the 10-K filed Mar 2, 2026 that are in none of the 1 earlier 10-Ks stored, back to Mar 3, 2025

borrowed pursuant ×2revolving credit ×2
Where each one is used
  • borrowed pursuant: Our current indebtedness and any future indebtedness we incur could adversely affect our financial condition. As of December 31, 2025 term loan indebtedness, excluding related discount, was $1,084.9 million, which $961.1 million was borrowed pursuant to the Barclays Revolving Credit Facility and the Barclays Term...
  • revolving credit: Our current indebtedness and any future indebtedness we incur could adversely affect our financial condition. As of December 31, 2025 term loan indebtedness, excluding related discount, was $1,084.9 million, which $961.1 million was borrowed pursuant to the Barclays Revolving Credit Facility and the Barclays Term...

The 10-K at sec.gov

Used at least twice, small words left out. Counted, not picked: a phrase can be new because the company renamed something.

What was taken out

1 paragraph of last year's Risk Factors with nothing like them now. The longest are quoted.

Across all companies
the federal No Surprises Act (H.R. 133) and similar insurer-provider payment dispute laws, which also may negatively impact our revenue.
In the 10-K filed Mar 3, 2025

Sources

Item 1A of each 10-K and 10-Q on EDGAR, quoted exactly. Each paragraph links to the filing at sec.gov.

Also

10-K change: what was reworded or cut, section by section.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/RDNT/export.csv") into a cell.

Next:10-K change
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.